2023
What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
Awada H, Gurnari C, Xie Z, Bewersdorf J, Zeidan A. What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. Cancers 2023, 15: 2248. PMID: 37190176, PMCID: PMC10137017, DOI: 10.3390/cancers15082248.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcute myeloid leukemiaMDS/AML patientsEarly clinical trialsPotential therapeutic agentAML patientsMultidrug combinationsClinical trialsMyeloid leukemiaMyeloid neoplasmsRational approachSingle agentCurrent managementTherapeutic potentialStandardized guidelinesTherapeutic agentsMutational characteristicsPatientsNeoplasmsLatest findingsGenomic factorsCellular adaptationAgentsHMA resistanceFailureLeukemia
2022
Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
Shallis RM, Bewersdorf JP, Stahl MF, Halene S, Zeidan AM. Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia? Cancers 2022, 14: 2434. PMID: 35626039, PMCID: PMC9140008, DOI: 10.3390/cancers14102434.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcute myeloid leukemiaMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationCD47/SIRPαIntensive induction therapyAvailable therapeutic optionsStem cell transplantationStandard of careAvailable clinical dataTesting of agentsInduction therapyMedian overallRefractory settingAggressive treatmentTim-3Immune checkpointsPreclinical rationaleTherapeutic optionsCell transplantationEfficacy dataClinical dataPatientsMolecular subgroupsTherapeutic agents
2016
Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities
Stahl M, Kim TK, Zeidan AM. Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. World Journal Of Stem Cells 2016, 8: 316-331. PMID: 27822339, PMCID: PMC5080639, DOI: 10.4252/wjsc.v8.i10.316.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLeukemia stem cellsNormal hematopoietic stem cellsHematopoietic stem cellsAcute myeloid leukemia stem cellsMyeloid leukemia stem cellsStem cellsAcute myeloid leukemiaMultitude of drugsNovel therapeutic agentsCancer stem cellsClinical trialsMyeloid leukemiaTherapeutic windowSelf-renewal pathwaysXenograft modelClinical developmentTherapeutic opportunitiesRational targetTherapeutic agentsLSC biologyAcceptable therapeutic windowDrugsCellsFunctional studiesLeukemia